Replies to post #164508 on Biotech Values

[mcbio]

Reverse engineering insulin analogs is technically easy, so there will likely be too many competitors for any of them to earn a hefty profit margin.

Thanks for the response. FWIW, I believe MYL/Biocon believe they are in the lead in this space. Also, it's unclear to me exactly how many other companies have detailed their plans in this space. Finally, at Biocon's current market cap, and given their existing revenue and numerous other ongoing programs, they could presumably still carve out enough of the generic insulin analog space to move the dial at this valuation IMO.